#HealthLawPReview2017 Wendy Parmet @NUSL @NUSLHealth transitions from government action (#Zika) to government inaction (#FlintWaterCrisis)

#HealthLawPReview2017: @georgejannas @BUSPH with sensible critique of global #ZikaVirus response & declaration of public health emergency

"No emergency exceptions to informed consent for research" during public health emergencies -- @georgejannas @BUSPH #HealthLawPReview2017

#HealthLawPReview2017 @georgejannas @BUSPH: @POTUS @realDonaldTrump has "America 1st, seal the borders" approach to public health emergency

#HealthLawPReview2017: The inimitable @georgejannas @BUSPH discussing #ZikaVirus, public health emergencies & successful #Rio2016 response

Great talk from @CohenProf @Harvard_Law @PetrieFlom discussing a banner year in reproductive technology at #HealthLawPReview2017

#HealthLawPReview2017: New publication from @CohenProf @PetrieFlom, @G_Q_Daley @harvardmed & @eadashi in @ScienceTM:

Relevant to @CohenProf @Harvard_Law talk #HealthLawPReview2017: The @US_FDA is prohibited from going germline

#healthlawpreview2017 @AzizaAhmed @NUSLHealth: Dangerous precedent set by Purvi Patel case -- DIY abortions unsafe!

#HealthLawPReview2017: @AzizaAhmed @NUSLHealth @NUSL discusses women's health. More on TRAP laws & abortion access:

#HealthLawPReview2017 Fascinating: trade secrets a new avenue for pharmaceutical development? What effect on dissemination of knowledge?

#HealthLawPReview2017 @AmeetSarpatwari @PORTAL_Research: naming & shaming likely to have mixed effect on drug prices moving forward

#HealthLawPReview2017 @PetrieFlom @Harvard_Law: @AmeetSarpatwari @PORTAL_Research @BWHResearch discusses Drug Pricing & Cost #policyethx

#HealthLawPReview2017: Dr. Jerry Avorn not impressed by current candidates for @US_FDA: poor idea to return to "government is the problem"

#HealthLawPReview2017: Dr Jerry Avorn discusses role of academic detailing, Alosa Health, @NaRCAD as protective mechanism in "post-fact" FDA

#HealthLawPReview2017 Dr. Jerry Avorn @NaRCAD, @PORTAL_Research, Dept. Pharmacoepidemiology & Pharmcoeconomics @BWHResearch & Alosa Health

#HealthLawPReview2017 @PetrieFlom Health Law Year in P/Review is now trending -- at least on my feed!

#HealthLawPReview2017 Holly Fernandez-Lynch @PetrieFlom: Congressional Review Act & new Midnight Rules Relief Act could threaten Common Rule

#HealthLawPReview2017 Holly Fernandez-Lynch: final Common Rule took years to develop but could be dismantled by new administration

#HealthLawPReview2017 @PetrieFlom: Final Common Rule arrived 1/19/2017 -- significant #IRB & #informedconsent changes in #21CC as well

#HealthLawPReview2017 @PetrieFlom: uncertainty WRT Precision Medicine & Cancer Moonshot moving forward -- no clearly defined outcome

#HealthLawPReview2017 @PetrieFlom Health Law Year in P/Review: Dr Jonathan Darrow takes us from Nixon's War on Cancer to the Cancer Moonshot

#HealthLawPReview2017 @PetrieFlom: previous #ACARepeal efforts symbolic -- @GOP still not prepared for prime time & have no replacement plan

#HealthLawPReview2017 @PetrieFlom: @HealthStew @HealthStewBlog with a resounding "No" to likelihood of single-payer, invokes Rolling Stones:

#healthlawpreview2017 @DemGovs @The_RGA -- states likely to have considerable input into Medicaid reforms -- popular among both parties!

#healthlawpreview2017 @PetrieFlom Health Law Year in P/Review: branding matters!

Obamacare less favorable than ACA:

#healthlawpreview2017 @DavidBlumenthal: "Trying to get past 'alternative facts' here..."

#healthlawpreview2017 @PetrieFlom Health Law P/Review: emerging theme -- uncertainty & lack of consensus with repeal/replace #Docs4Coverage